Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 14.25p 23,462 08:00:00
Bid Price Offer Price High Price Low Price Open Price
14.00p 14.50p 14.25p 14.25p 14.25p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.6 -4.2 - 13.29

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Share Charts

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart

Intraday Evgen Pharma Chart

Intraday Evgen Pharma Chart

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date Time Title Posts
25/4/201817:18Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer141
26/6/201707:38Evgen Pharma Plc Investor Presentation-
13/6/201709:45Evgen Pharma Interview-
29/11/201608:27Evgen Pharma (EVG) chief executive Stephen Franklin39

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-04-25 15:29:3414.1517,6672,499.88O
2018-04-25 15:15:5614.186,172874.88O
2018-04-25 15:15:2214.186,862972.69O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Evgen Pharma Daily Update: Evgen Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 14.25p.
Evgen Pharma has a 4 week average price of 12.25p and a 12 week average price of 12.25p.
The 1 year high share price is 29.38p while the 1 year low share price is currently 12p.
There are currently 93,276,858 shares in issue and the average daily traded volume is 124,979 shares. The market capitalisation of Evgen Pharma is £13,291,952.27.
rathean: Agreed #Tilly99, share price discounts huge upside. Great entry point, it'll rise quickly when it goes
dave444: I would not be surprised if it hit 12p but a £1/share price would not surprise me by February
timbo003: There doesn't seem to be any material event behind the recent rise, so presumably the reason is just another Pump and Dump. However, if the share price ends up higher than where it started , it will have served a useful purpose. I suspect the company will want to find a bit of cash from somewhere before they get the first readout from the two ongoing clinical studies and according to the last Hardman report they will be running on empty by March next year. If the cash is to come from an equity based fund raise (which seems likely), then the higher the price the better as far as I am concerned.
ny boy: The Company needs to issue a statement re the share price rise, I think it will come in the next few hours.
pdt: Another good piece of research on Sulforaphane and breast cancer; Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells hTTp:// A bit disappointing that the share price is drifting lower. That will not help the inevitable fund raise. Hopefully, there will be some positive news before they complete that. I have been buying on the way down but now I have probably as many as I want to hold at this stage.
timbo003: This week's (unexpected) performance has to be worth an animated gif! I'm not sure what the catalyst is for this recent rise, a patent grant (even in the US) doesn't normally have an effect of this magnitude on the share price.
timbo003: Presumably this new article on Proactiveinvestor was the catalyst for the excitement today: It's well written but contains no new news, so it wouldn't surprise me if the share price drifts back down again. I suspect the next significant news will be MRHA approval for the Metastatic breast cancer study
call-logger: Subject to the Court sanctioning the Scheme and the satisfaction of certain other outstanding conditions, it is expected that the last day for dealings in Evolution Shares will be 6 December 2011 and the Scheme will become effective on 7 December 2011. If you're selling, the takeover date doesn't really matter to you. The share price is now purely based on the market's view of Investec
plast: well if that is the result to the share price, then they can sell some more.
msy: No share price movement to the following news? BES could make full bid for Evolution if strategic alliance goes well LISBON (Thomson Financial) - Banco Espirito Santo could make a full bid for the Evolution Group, in which it bought a 9.95 pct stake yesterday, if the strategic alliance between the Portuguese bank and the UK broker goes well, the Daily Telegraph reported, without citing a source. According to the newspaper, BES bought the stake in Evolution to offer international clients access to the London market through the UK-based financial holding's investment arm. If the arrangement works well, BES may make an offer for the whole of the UK business which is worth 260 mln stg, the paper said. Yesterday, BES investment unit BESI said it acquired its 9.95 pct stake for around 26.1 mln stg (about 35.5 mln eur). Evolution might be attractive to a buyer because the volatile earnings from its investment banking business were offset by more steady profits from its asset-management business, gained when it bought Williams de Broe from ING in 2006, the paper added.
Evgen Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180426 07:54:53